Guardant Health, Inc. - Common Stock (NQ:GH)

185.32 +2.73 (+1.50%)

Delayed Quote Updated: 12:47 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023

May 05, 2023

From Guardant Health, Inc.

Via Business Wire

New Artificial Intelligence Tool Can Diagnose Colon Cancer

May 03, 2023

A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...

Via PressReach

Topics Artificial Intelligence Death

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference

April 27, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

April 25, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

April 21, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023

April 19, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Earnings Perspective: Return On Capital Employed ↗

March 16, 2023

Via Benzinga

Looking Into Guardant Health's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Analyst Expectations for Guardant Health's Future ↗

February 27, 2023

Via Benzinga

Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

April 18, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting

April 11, 2023

From Guardant Health, Inc.

Via Business Wire

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle ↗

April 03, 2023

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell.

Via Investor's Business Daily

Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence

March 21, 2023

From Guardant Health, Inc.

Via Business Wire

Earnings Outlook For Guardant Health ↗

February 22, 2023

Via Benzinga

Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

March 10, 2023

From Guardant Health, Inc.

Via Business Wire

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market ↗

March 06, 2023

Investing now is an admittedly risky bet, but the payoff could be massive.

Via The Motley Fool

Musa Tariq Joins Guardant Health Board of Directors

February 27, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

February 23, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming March Investor Conferences

February 17, 2023

From Guardant Health, Inc.

Via Business Wire

25 AI Stocks to Buy Right Now ↗

February 16, 2023

Looking to benefit from the AI boom started by ChatGPT? Here are the best AI stocks to buy for the emerging market frenzy.

Via InvestorPlace

Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer

February 15, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer

February 08, 2023

From Guardant Health, Inc.

Via Business Wire

Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development ↗

February 04, 2023

Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...

Via Talk Markets

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

February 02, 2023

From Guardant Health Inc.

Via Business Wire

Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina

February 02, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 01, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery

January 31, 2023

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.